Talphera (TLPH) Projected to Post Quarterly Earnings on Thursday

Talphera (NASDAQ:TLPH) will likely be posting its Q4 2025 results after the market closes on Thursday, March 5th. Analysts expect Talphera to post earnings of ($0.0750) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Tuesday, March 24, 2026 at 4:00 PM ET.

Talphera Price Performance

NASDAQ:TLPH opened at $0.90 on Wednesday. The business has a 50 day simple moving average of $0.97 and a 200-day simple moving average of $1.02. The firm has a market capitalization of $41.73 million, a price-to-earnings ratio of -2.36 and a beta of 0.47. Talphera has a 1 year low of $0.38 and a 1 year high of $1.57.

Insider Activity at Talphera

In related news, insider Shakil Aslam purchased 35,000 shares of Talphera stock in a transaction that occurred on Thursday, February 12th. The stock was purchased at an average price of $0.81 per share, for a total transaction of $28,350.00. Following the transaction, the insider directly owned 83,178 shares in the company, valued at approximately $67,374.18. This trade represents a 72.65% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Raffi Asadorian bought 45,000 shares of the firm’s stock in a transaction on Thursday, February 12th. The stock was acquired at an average cost of $0.81 per share, for a total transaction of $36,450.00. Following the completion of the purchase, the chief financial officer directly owned 91,256 shares in the company, valued at approximately $73,917.36. This represents a 97.28% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last ninety days, insiders have purchased 220,364 shares of company stock valued at $178,495. Insiders own 5.70% of the company’s stock.

Institutional Investors Weigh In On Talphera

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TLPH. Group One Trading LLC raised its position in Talphera by 3,224.0% in the 3rd quarter. Group One Trading LLC now owns 30,415 shares of the company’s stock valued at $27,000 after purchasing an additional 29,500 shares in the last quarter. Virtu Financial LLC purchased a new stake in Talphera in the third quarter valued at approximately $29,000. Persistent Asset Partners Ltd acquired a new position in Talphera in the 4th quarter valued at about $42,000. Mariner LLC increased its holdings in shares of Talphera by 132.0% in the fourth quarter. Mariner LLC now owns 58,000 shares of the company’s stock valued at $66,000 after purchasing an additional 33,000 shares during the period. Finally, Dauntless Investment Group LLC purchased a new position in Talphera during the 3rd quarter worth $89,000. Institutional investors and hedge funds own 37.67% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Talphera in a report on Wednesday, January 21st. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $6.00.

About Talphera

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe.